Pfizer Signs Big Bang Deal With Aurobindo For Larger Presence in Generics; Biosimilars Next ?
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - Pfizer has turned its attention to establishing a bigger presence in the U.S. for marketing generic drugs, terming it as an "engine of positive growth." The world's largest drug maker has signed a series of licensing agreements with India's Aurobindo Pharma to acquire rights of 39 generic solid oral dose products and 12 sterile injectable products
You may also be interested in...
India’s Aurobindo Pharma lands U.S. FDA approval of generic Seroquel despite warning letter issued last year.